755039-90-8

Basic information

• Product Name: CyclohexanaMine, 4-[4-(cyclopropylMethyl)-1-piperazinyl]-, cis-
• Synonyms: CyclohexanaMine, 4-[4-(cyclopropylMethyl)-1-piperazinyl]-, cis-;Cis-4-[4-(cyclopropylMethyl)-1-piperazinyl]-cyclohexanaMine hydrochloride (1:);CyclohexanaMine, 4-[4-(cyclopropylMethyl)-1-piperazinyl]-, (Hydrochloride) (1:3), Cis-;(1s,4s)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexanamine
• CAS NO: 755039-90-8
• Molecular Formula: C₁₄H₂₇N₃
• Molecular Weight: 237.38428
• Mol File: 755039-90-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 326.1°C at 760 mmHg
• Flash Point: 148.9°C
• Appearance: /
• Density: 1.063g/cm³
• Vapor Pressure: 0.00022mmHg at 25°C
• Refractive Index: 1.552
• PKA: 10.54±0.70(Predicted)
• CAS DataBase Reference: CyclohexanaMine, 4-[4-(cyclopropylMethyl)-1-piperazinyl]-, cis-(CAS DataBase Reference)
• NIST Chemistry Reference: CyclohexanaMine, 4-[4-(cyclopropylMethyl)-1-piperazinyl]-, cis-(755039-90-8)
• EPA Substance Registry System: CyclohexanaMine, 4-[4-(cyclopropylMethyl)-1-piperazinyl]-, cis-(755039-90-8)

Safety Data

• Hazardous Substances Data: 755039-90-8(Hazardous Substances Data)

Usage

General Description

Cyclohexanamine, 4-[4-(cyclopropylmethyl)-1-piperazinyl]-, cis- is a chemical compound that is composed of cyclohexanamine and a piperazine ring. It is present in the form of a cis isomer and contains a cyclopropylmethyl moiety. Cyclohexanamine, 4-[4-(cyclopropylmethyl)-1-piperazinyl]-, cis- is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various drugs. It may also be used in research and development for the creation of new medicines and chemical compounds. Additionally, it may have potential applications in the field of organic chemistry and chemical engineering.

InChI:InChI=1/C14H27N3/c15-13-3-5-14(6-4-13)17-9-7-16(8-10-17)11-12-1-2-12/h12-14H,1-11,15H2/t13-,14+

Upstream product

• 57184-25-5 1-cyclopropylmethylpiperazine 
• 373608-50-5 4-cyclopropylmethylpiperazine-1-carboxylic acid tert-butyl ester 
• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 373608-42-5 1-(cyclopropylmethyl)piperazine dihydrochloride 
• 149506-79-6 4-(dibenzylamino)cyclohexanone 
• 50910-54-8 trans-4-aminocyclohexanol hydrochloride 
• 149506-81-0 trans-4-(dibenzylamino)cyclohexanol 
• 755039-88-4 (cis)-N,N-dibenzyl-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexanamine 

Downstream Products

• 1280664-94-9 7-[[(7R)-8-Cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-N-[(cis)-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-2,3-dihydrobenzofuran-4-carboxamide 
• 1280665-14-6 7-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-N-[(cis)-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-2,2-dimethyl-3H-benzofuran-4-carboxamide 
• 1280665-47-5 N-[(cis)-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-7-[[(7R)-7-ethyl-8-isopropyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-2,3-dihydrobenzofuran-4-carboxamide 
• 1280665-46-4 N-[(cis)-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-7-[[(7S)-7-ethyl-8-isopropyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-2,3-dihydrobenzofuran-4-carboxamide 

Relevant articles and documents

CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS

This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions.

DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.

DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES

The present invention relates to the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.